SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event

reported): September 21, 2015

(Exact Name of Registrant as Specified

The Gridiron Building

C/O Pearl Cohen Zedek Latzer Baratz UK

London, N1C 4AG, United Kingdom

(Address of Principal Executive Offices

Registrant's telephone number,

including area code +44-203-318-3004

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction

(e) CEO Employment Agreement

On September 21, 2015, Akari Therapeutics Plc ("Akari"

or the "Company"), upon the recommendation of the Compensation Committee of the Company's Board of Directors

(the "Compensation Committee"), entered into the Executive Employment Agreement by and between the Company and

its Chief Executive Officer, Gur Roshwalb, M.D. (the "CEO Employment Agreement"). The CEO Employment Agreement

is effective as of September 18, 2015, and has a term of one year with automatic renewals for successive one-year periods unless

terminated by either party upon three-months' notice prior to the expiration of the current term. Pursuant to the terms of

the CEO Employment Agreement, Dr. Roshwalb will receive an annual base salary of $375,000, subject to review on an annual basis.

Dr. Roshwalb will also be entitled to an annual cash bonus with a target of 40% of base salary, provided that the actual amount

of such bonus may be greater or less that the target amount.

The CEO Employment Agreement also provides that Dr. Roshwalb

will be entitled to a stock option grant to purchase 32,543,700 Ordinary Shares (equivalent to 325,437 American Depositary Shares

("ADSs")), par value par value 0.01, of the Company ("Ordinary Shares"). This option

grant was granted on September 21, 2015, with a share exercise price equal to $0.3221 per share (or $32.21 per ADS), which is the

fair market value on the date of grant, as defined in the Company's 2014 Equity Incentive Plan (the "Plan").

The option grant was granted pursuant to and is governed by the terms of the Plan.

Upon termination of Dr. Roshwalb's employment Without

Cause (as defined therein), by Dr. Roshwalb for Good Reason or upon Expiration of the Term (as defined therein), in addition to

any accrued but unpaid base salary and expense reimbursement, he shall be entitled to receive an amount equal to 12 months of base

salary at the highest annualized rate in effect at any time before the employment terminates payable in substantially equal installments.

Dr. Roshwalb shall also be entitled to COBRA continuation coverage paid in full by the Company for up to a maximum of 12 months

following the date of termination.

Upon termination of Dr. Roshwalb's employment Without

Cause (as defined therein) or by Dr. Roshwalb for Good Reason following a Change of Control (as defined therein), unless the Change

of Control happens for less than $225 million, in addition to any accrued but unpaid base salary and expense reimbursement, he

shall be entitled to receive an amount equal to 18 months of one and a half times annual base salary at the highest annualized

rate in effect at any time before the employment terminates payable in substantially equal installments and the target annual performance

bonus that he would have been entitled to for the year in which termination was effective. Dr. Roshwalb shall also be entitled

to COBRA continuation coverage paid in full by the Company for up to a maximum of 18 months following the date of termination.

The Company is entitled to terminate Dr. Roshwalb's employment immediately, under certain terms as specified in the CEO Employment

The CEO Employment Agreement also contains restrictive covenants

for the Company's benefit and Dr. Roshwalb is required to maintain the confidentiality of the Company's confidential

The foregoing description of the CEO Employment Agreement does

not purport to be complete and is qualified in its entirety by reference to the CEO Employment Agreement which is attached as Exhibit

10.1 to this Current Report on Form 8-K.

CFO Employment Agreement

On September 21, 2015, the Company, upon the recommendation

of the Compensation Committee, entered into the Executive Employment Agreement by and between the Company and its Chief Financial

Officer, Dov Elefant (the "CFO Employment Agreement"). The CFO Employment Agreement is effective as of September

18, 2015, and has a term of one year with automatic renewals for successive one-year periods unless terminated by either party

upon three-months' notice prior to the expiration of the current term. Pursuant to the terms of the CFO Employment Agreement,

Mr. Elefant will receive an annual base salary of $200,000, subject to review on an annual basis. Mr. Elefant will also be entitled

to an annual cash bonus with a target of 25% of base salary, provided that the actual amount of such bonus may be greater or less

than the target amount.

The CFO Employment Agreement also provides that Mr. Elefant

will be entitled to a stock option grant to purchase 4,067,963 Ordinary Shares (equivalent to 40,679 ADSs). This option grant was

granted on September 21, 2015, with a share exercise price equal to $0.3221 per share (or $32.21 per ADS), which is the fair market

value on the date of grant, as defined in the Plan. The option grant was granted pursuant to and is governed by the terms of the

Upon termination of Mr. Elefant's employment Without Cause

(as defined therein), by Mr. Elefant for Good Reason or upon Expiration of the Term (as defined therein), in addition to any accrued

but unpaid base salary and expense reimbursement, he shall be entitled to receive an amount equal to 12 months of base salary at

the highest annualized rate in effect at any time before the employment terminates payable in substantially equal installments.

Mr. Elefant shall also be entitled to COBRA continuation coverage paid in full by the Company for up to a maximum of 12 months

following the date of termination.

Upon termination of Mr. Elefant's employment Without Cause

(as defined therein) or by Mr. Elefant for good reason following a Change of Control (as defined therein), in addition to any accrued

but unpaid base salary and expense reimbursement, he shall be entitled to receive an amount equal to 18 months of one and a half

times annual base salary at the highest annualized rate in effect at any time before the employment terminates payable in substantially

equal installments and the target annual performance bonus that he would have been entitled to for the year in which termination

was effective. Mr. Elefant shall also be entitled to COBRA continuation coverage paid in full by us for up to a maximum of 18 months

following the date of termination. The Company is entitled to terminate Mr. Elefant's employment immediately, under certain

terms as specified in the CFO Employment Agreement.

The CFO Employment Agreement also contains restrictive covenants

for the Company's benefit and Mr. Elefant is required to maintain the confidentiality of the Company's confidential

The foregoing description of the CFO Employment Agreement does

not purport to be complete and is qualified in its entirety by reference to the CFO Employment Agreement which is attached as Exhibit

10.2 to this Current Report on Form 8-K.

COO Employment Contract

On September 21, 2015, the Company, upon the receommendation

of the Compensation Committee, approved and entered into the Employment Contract by and between the Company and its Chief Operating

Officer, Clive Richardson (the "COO Employment Agreement"). The COO Employment Agreement is effective as of

September 16, 2015, and shall continue until terminated by either party upon not less than six months' prior written notice.

Pursuant to the terms of the COO Employment Agreement, Mr. Richardson will receive an annual base salary of 210,000, subject

to review on an annual basis. Mr. Richardson will also be entitled to an annual cash bonus with a target of 40% of base salary.

The COO Employment Agreement also provides that Mr. Richardson

will be entitled to a stock option grant to purchase 16,271,850 Ordinary Shares (equivalent to 162,718 ADSs). This option grant

was granted on September 21, 2015, with a share exercise price equal to $0.3221 per share (or $32.21 per ADS), which is the fair

market value on the date of grant, as defined in the Plan. The option grant was granted pursuant to and is governed by the terms

Upon termination of Mr. Richardson's employment, he shall

be entitled to receive an amount equal to one and a half times the sum of his annual base salary in effect on the termination date

and the target annual performance bonus that he would have been entitled to for the year in which Mr. Richardson's termination

The COO Employment Agreement also contains restrictive covenants

for the Company's benefit and Mr. Richardson is required to maintain the confidentiality of the Company's confidential